Circulating and histological expression of THBS2 has been demonstrated to be a novel diagnostic and prognostic biomarker for patients with pancreatic cancer [15–17], distal cholangiocarcinoma [15, 18], lung cancer [19, 20], and colorectal cancer [21, 22]. This evidence concerns the gene THBS2 and familial pancreatic carcinoma.